A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Relmada Therapeutics (RLMD) is back in focus after releasing 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, alongside a roughly US$160 million oversubscribed private placement. See our latest analysis for Relmada Therapeutics. The 1 day share price return of 61.1% to US$7.17, alongside a 30 day share price return of 84.8% and very large 1 year total shareholder return, suggests momentum has accelerated sharply as the NDV-01 data and US$160m private placement reshape how investors view Relmada's risk and funding outlook. If this jump in sentiment has you looking beyond a single biotech name, it could be a good moment to scan our 32 healthcare AI stocks and see what else is moving in the sector. With RLMD still trading below the US$10.75 analyst price target even after a 61.1% one-day jump, the key question now is simple: are investors still underestimating NDV-01 and the new funding, or is the market already pricing in future growth?
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Relmada Therapeutics (RLMD) was given a new $10.00 price target by Mizuho.MarketBeat
- Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026GlobeNewswire
- 50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 11/13/25 - Miss
RLMD
Sec Filings
- 3/9/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- RLMD's page on the SEC website